PAK1 Expression in Pancreatic Cancer: Clinicopathological Characteristics and Prognostic Significance.

PAK1 immunohistochemistry p21-activated kinases pancreatic cancer survival

Journal

Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771

Informations de publication

Date de publication:
2019
Historique:
received: 10 10 2018
accepted: 17 01 2019
entrez: 26 2 2019
pubmed: 26 2 2019
medline: 26 2 2019
Statut: epublish

Résumé

Improvement of the management of pancreatic cancer requires a better understanding of the genetic and molecular changes responsible for the development of the disease. The family of p21-activated kinases (PAKs) and especially PAK1 appears to mediate many cellular processes that contribute to the development and progression of pancreatic cancer, but the clinical relevance of PAK1 expression with the disease still remains unclear. Aim of the study was to assess the clinical value and the potential prognostic significance of PAK1 in pancreatic adenocarcinoma. We investigated the relationship between the PAK1 expression and the clinical and histopathologic characteristics of pancreatic cancer patients and the potential significance of PAK1 on survival. We examined tissue samples from 51 patients operated for pancreatic cancer. PAK1 expression was investigated with immunohistochemistry and correlated to clinicopathological parameters. PAK1 was detected in all tumor samples and high expression was found in most patients. High PAK1 expression was also associated with younger age and well-differentiated tumors, but no association was found between PAK1 expression and Tumor-Node-Metastasis stage as well as deceased or alive status on follow-up. Moderate to high PAK1 expression favored higher 6-month and 1-year survival and low PAK1 expression 2-year survival but without statistical significance. Our results indicate that PAK1 could potentially be used as a prognostic marker in pancreatic cancer. Further studies could clarify whether utilization of PAK1 in therapeutic protocols for the treatment of pancreatic cancer will render them more effective.

Sections du résumé

BACKGROUND BACKGROUND
Improvement of the management of pancreatic cancer requires a better understanding of the genetic and molecular changes responsible for the development of the disease. The family of p21-activated kinases (PAKs) and especially PAK1 appears to mediate many cellular processes that contribute to the development and progression of pancreatic cancer, but the clinical relevance of PAK1 expression with the disease still remains unclear. Aim of the study was to assess the clinical value and the potential prognostic significance of PAK1 in pancreatic adenocarcinoma.
METHODS METHODS
We investigated the relationship between the PAK1 expression and the clinical and histopathologic characteristics of pancreatic cancer patients and the potential significance of PAK1 on survival. We examined tissue samples from 51 patients operated for pancreatic cancer. PAK1 expression was investigated with immunohistochemistry and correlated to clinicopathological parameters.
RESULTS RESULTS
PAK1 was detected in all tumor samples and high expression was found in most patients. High PAK1 expression was also associated with younger age and well-differentiated tumors, but no association was found between PAK1 expression and Tumor-Node-Metastasis stage as well as deceased or alive status on follow-up. Moderate to high PAK1 expression favored higher 6-month and 1-year survival and low PAK1 expression 2-year survival but without statistical significance.
CONCLUSIONS CONCLUSIONS
Our results indicate that PAK1 could potentially be used as a prognostic marker in pancreatic cancer. Further studies could clarify whether utilization of PAK1 in therapeutic protocols for the treatment of pancreatic cancer will render them more effective.

Identifiants

DOI: 10.1177/1179554919831990 PMID: 30799970 PMC: PMC6379789
pubmed: 30799970
doi: 10.1177/1179554919831990
pii: 10.1177_1179554919831990
pmc: PMC6379789
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1179554919831990

Déclaration de conflit d'intérêts

Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Circ Res. 2002 Apr 5;90(6):697-702
pubmed: 11934838
J Cell Physiol. 2002 Nov;193(2):133-44
pubmed: 12384990
Cell Signal. 2003 Dec;15(12):1099-109
pubmed: 14575865
J Natl Cancer Inst. 2006 May 17;98(10):671-80
pubmed: 16705121
Nat Rev Cancer. 2006 Jun;6(6):459-71
pubmed: 16723992
J Mol Biol. 2006 Aug 11;361(2):312-26
pubmed: 16837009
J Urol. 2007 Sep;178(3 Pt 1):1073-9
pubmed: 17644138
Chem Biol. 2008 Apr;15(4):322-31
pubmed: 18420139
Trends Biochem Sci. 2008 Aug;33(8):394-403
pubmed: 18639460
Cancer Res. 2009 Feb 1;69(3):765-74
pubmed: 19176398
Oncogene. 2009 Jul 16;28(28):2545-55
pubmed: 19465939
BMC Cancer. 2010 Apr 28;10:164
pubmed: 20426825
Int J Oncol. 2010 Oct;37(4):951-62
pubmed: 20811717
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Gastroenterol Jpn. 1990 Apr;25(2):236-43
pubmed: 2161375
Arch Pathol Lab Med. 2011 Jun;135(6):716-27
pubmed: 21631264
World J Gastroenterol. 2011 Jun 28;17(24):2897-908
pubmed: 21734801
Mol Cancer Ther. 2012 Jan;11(1):24-33
pubmed: 22027689
Cancer Lett. 2012 Apr 1;317(1):24-32
pubmed: 22085492
Mol Carcinog. 2012 Jan;51(1):3-13
pubmed: 22162227
Oncol Rep. 2012 May;27(5):1435-42
pubmed: 22293972
Zhonghua Bing Li Xue Za Zhi. 2012 Jan;41(1):62-5
pubmed: 22455858
J Med Chem. 2012 May 24;55(10):4728-39
pubmed: 22554206
EMBO Rep. 2012 Jun 29;13(7):653-9
pubmed: 22653441
Cancer Res. 2012 Nov 15;72(22):5966-75
pubmed: 22983922
Mol Endocrinol. 2013 Jul;27(7):1048-64
pubmed: 23744893
PLoS One. 2013 Nov 13;8(11):e80665
pubmed: 24236193
Cancer Lett. 2014 May 1;346(2):264-72
pubmed: 24491405
Oncogene. 2015 Jan 22;34(4):455-64
pubmed: 24561527
J Pathol. 2014 Dec;234(4):502-13
pubmed: 25074413
BMC Cancer. 2014 Sep 03;14:650
pubmed: 25182632
J Surg Res. 2015 Jun 1;196(1):130-5
pubmed: 25791829
BMC Cancer. 2016 Jan 16;16:24
pubmed: 26774265
World J Gastroenterol. 2018 Sep 7;24(33):3709-3723
pubmed: 30197477
Nature. 1994 Jan 6;367(6458):40-6
pubmed: 8107774

Auteurs

Nikolaos Symeonidis (N)

Postgraduate Program in Hepatobiliary/Pancreatic Surgery, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
2nd Surgical Propedeutic Department, Hippokratio General Hospital, Thessaloniki, Greece.
ORCID: 0000-0001-7703-7854

Maria Lambropoulou (M)

Laboratory of Histology-Embryology, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Efstathios Pavlidis (E)

Postgraduate Program in Hepatobiliary/Pancreatic Surgery, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Constantinos Anagnostopoulos (C)

Laboratory of Biochemistry, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Alexandra Tsaroucha (A)

2nd Department of Surgery and Laboratory of Experimental Surgery-Postgraduate Program in Hepatobiliary/Pancreatic Surgery, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Athanasia Kotini (A)

Laboratory of Medical Physics, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Christina Nikolaidou (C)

Laboratory of Histology-Embryology, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Anastasia Kiziridou (A)

Department of Pathology, Theagenio Anticancer Hospital, Thessaloniki, Greece.

Constantinos Simopoulos (C)

2nd Department of Surgery and Laboratory of Experimental Surgery-Postgraduate Program in Hepatobiliary/Pancreatic Surgery, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Classifications MeSH